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Abstract 
Background: Syncytin-1 and 2, human fusogenic glycoproteins encoded by the env genes of the endogenous 
retroviral loci ERVWE1 and ERVFRDE1, respectively, contribute to the differentiation of multinucleated syncytiotropho-
blast in chorionic villi. In non-trophoblastic cells, however, the expression of syncytins has to be suppressed to avoid 
potential pathogenic effects. Previously, we have shown that the transcriptional suppression of ERVWE1 promoter is 
controlled epigenetically by DNA methylation and chromatin modifications. In this study, we describe the aberrant 
expression of syncytin-1 in biopsies of testicular germ cell tumors.
Results: We found efficient expression and splicing of syncytin-1 in seminomas and mixed germ cell tumors with 
seminoma component. Although another fusogenic gene, syncytin-2 was also derepressed in seminomas, its expres-
sion was significantly lower than that of syncytin-1. Neither the transcription factor GCM1 nor the increased copy 
number of ERVWE1 were sufficient for this aberrant expression of syncytin-1 in seminomas. In accordance with our 
recent finding of the highly increased expression of TET1 dioxygenase in most seminomas, the ERVWE1 promoter was 
significantly hypomethylated in comparison with the matched controls. In contrast, 5-hydroxymethylcytosine levels 
were not detectable at the ERVWE1 promoter. We further describe that another endogenous retroviral element adja-
cent to ERVWE1 remains transcriptionally suppressed and two additional HERV-W family members are only slightly 
upregulated in seminomas.
Conclusions: We conclude that DNA demethylation of the ERVWE1 promoter in seminomas is a prerequisite for 
syncytin-1 derepression. We propose the spliced syncytin-1 expression as a marker of seminoma and suggest that 
aberrant expression of endogenous retroviruses might be a correlate of the hypomethylated genome of seminomas.
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Background
Human endogenous retroviruses (HERVs) represent the 
remnants of the past retroviral infections in the human 
lineage that penetrated the germ line leaving behind the 
heritable proviral copies in the human genome. With a 
few exceptions, HERVs have become defective by grad-
ual accumulation of inactivating mutations in their open 
reading frames. Transcription of most HERV copies is 
silenced by epigenetic mechanisms such as DNA meth-
ylation and association with histone molecules marked 
by suppressive modifications.
Although endogenous retroviruses are widely employed 
in genome evolution as a source of regulatory sequences 
and interfere with new exogenous infections, there are 
few documented captures of intact retrovirus-encoded 
proteins for cellular functions. Syncytin-1 and -2 are 
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retroviral envelope glycoproteins whose original receptor-
mediated virus-to-cell fusion capacity evolved towards 
cell-to-cell fusion [1–3]. This fusogenic potential unfolds 
in all respects in placenta where syncytins are indispensa-
ble for syncytiotrophoblast differentiation. Only recently, 
the contribution of fusogenic syncytins to myogenesis and 
osteoclast fusion was suggested for mouse and human [1, 
4]. On the other hand, the expression of syncytins must 
be suppressed in non-syncytial tissues, and, therefore, the 
capture of fusogenic retroviral envelope glycoproteins has 
to be accompanied by the gain of tissue-specific regula-
tion. The importance of tissue-specific regulation of syn-
cytin-1 is even underscored by the ubiquitous expression 
of its specific receptors, the human sodium-dependent 
neutral amino acid transporters type 1 and 2 (ASCT1, 
also known as SLC1A4, and ASCT2/SLC1A5) [5, 6].
Syncytin-1 is encoded by the env gene of the ERVWE1 
provirus (NCBI accepted name ERVW1), a prototype 
member of the HERV-W family, localized on chromo-
some 7 [7, 8]. Both cis and trans regulatory circuits have 
been described [9, 10]; however, the tissue-specificity of 
syncytin-1 expression is controlled epigenetically. We 
and others demonstrated that the ERVWE1 transcription 
was regulated by DNA methylation and trimethylation 
of H3K9 of the ERVWE1 5′ LTR [11–14]. Furthermore, 
we showed that the splicing of ERVWE1 mRNA occurrs 
in trophoblastic but not in non-placental cells [13] and 
serves as an additional control mechanism. Syncytin-2 
encoded by the env gene of a unique member of the 
HERV-FRD family, ERVFRDE1 (NCBI accepted name 
ERVFRD1), is also important for the fusion of human 
cytotrophoblast [15]. Like ERVWE1, ERVFRDE1 is also 
regulated epigenetically [14, 16], but the role of DNA 
methylation and splicing is less understood.
Aberrant expression of Syncytin-1 has been reported in 
multiple tumor types, but epigenetically-based evidence 
is available just for endometrial carcinomas [17, 18] and 
several samples of testicular tumors without exact char-
acterization [13, 14]. Testicular germ cell tumors (GCT) 
originate from embryonic primordial germ cells (PGC) or 
gonocytes as in situ neoplasias and transform into semino-
mas. Non-seminomas require further development, prob-
ably with reprogramming and dedifferentiation steps [19]. 
GCTs maintain, to a various extent, the epigenetic char-
acteristics of their PGC precursors, i.e., DNA hypometh-
ylation and low levels of H3K9 trimethylation [20, 21]. 
Comparison of seminomas and non-seminomas showed 
a lower level of genome methylation in seminomas and 
increased methylation in non-seminomas [22–26]. This 
again suggests that seminomas and non-seminomas arise 
in distinct periods of the PGC development with different 
degrees of cell differentiation. Recently published analy-
ses of the transcriptional and epigenetic landscape during 
human PGC development revealed progressive erasure of 
DNA methylation not only from the global genome, but 
also from the transposable elements [27–29].
The deeply hypomethylated genome of seminoma cells 
has been recently correlated with elevated expression 
of the TET1 enzyme in GCTs [30]. The DNA demeth-
ylation activity of TET dioxygenases proceeds through 
5-hydroxymethylcytosine (5-hmC) intermediate [31], 
which subsequently converts to 5-formylcytosine (5-fC), 
5-carboxycytosine and unmodified cytosine (C) [32, 33]. 
At least in mouse, Tet1 and Tet2 expression has been 
observed in late PGCs [34] and together with the repres-
sion of de novo DNA methyltransferases [35] create the 
hypomethylated germ line genome.
Based on the knowledge of DNA hypomethylation 
in GCTs and the observation of syncytin-1 expression 
in testicular tumors [13, 14], we explored the ERVWE1 
expression systematically within a panel of GCTs with 
particular respect given to discrimination between 
seminomas and non-seminoma GCTs. In addition, we 
included several samples of lymphomas and endometrial 
carcinomas in our analysis because of (1) the presence of 
multinuclear giant Reed-Sternberg cells in Hodgkin lym-
phomas [36], (2) the detection of full-length ERVWE1 
mRNA in endometrial carcinomas [17, 18, 37], and (3) 
the recently described increased expression of DNA 
demethylating dioxygenases TET2 and TET3 in semino-
mas, lymphomas and endometrial carcinomas [30] that 
could contribute to ERVWE1 transcriptional derepres-
sion. We estimated, for the first time, the levels of both 
5-methylcytosine (5-mC) and 5-hmC modifications at 
the ERVWE1 promoter within the 5′LTR. We also exam-
ined the transcription level of four other endogenous ret-
roviruses, including ERVFRDE1, in the GCTs.
Methods
Tissue samples
Testicular samples were collected from patients who 
were surgically treated at the Institute of Urology, Uni-
versity Hospital Kralovske Vinohrady, and Third Fac-
ulty of Medicine, Charles University between years 
2011–2015. Histological classification and TNM staging 
were done in accordance with WHO classification [19]. 
Lymphoma samples were acquired from the Department 
of Otorhinolaryngology, University Hospital Kralovske 
Vinohrady, and Department of Surgery, University Hos-
pital Kralovske Vinohrady. Endometrial carcinomas and 
six healthy term placental samples were obtained from 
the Department of Obstetrics and Gynecology, Univer-
sity Hospital Kralovske Vinohrady. Immediately after the 
surgery, the samples were frozen and stored in −80 °C.
Our extensive set of post-pubertal testicular malignant 
GCT samples contained 30 pure seminomas, one scar 
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after the seminoma, and 17 non-seminomas. The non-
seminomas included 12 mixed GCTs, two pure embryo-
nal carcinomas, two pure teratomas, and one pure yolk 
sac tumor. For the majority of cancer biopsies, the tumor-
matched controls were collected from the adjacent tis-
sue not affected macroscopically with the GCT. In some 
cases, two biopsies from distinct parts of the tumor were 
analyzed. The set also contained ten samples of the testes 
not diagnosed with the GCTs (termed non-GCT controls 
throughout the text). The non-GCT controls included 
five samples of atrophic testes, one sample with testicu-
lar necrotic tissue, two testis after ischemia–reperfusion 
injury, and two testis without GCT. Our set of malignant 
human tumor samples further contained tumors of non-
germ cell origin, specifically three Hodgkin lymphomas 
and five non-Hodgkin lymphomas, and seven endome-
trial carcinomas, including six endometrioid and one 
non-endometrioid. Description of tumor samples is indi-
cated in Additional file 1: Table S1.
Cell culture procedures
Choriocarcinoma BeWo cells were maintained in F-12 
and MEM-D media mixed 1:1 (Sigma) supplemented 
with 1% NaHCO3, 10% FBS. Seminoma TCam-2 cells 
were maintained in RPMI-1640 (Sigma) supplemented 
with 10% FBS and 0.3  mg/ml  l-glutamine. A mix of 
penicillin and streptomycin (0.1 mg/ml each) was added 
to both cell lines in culture. Cells were kept at 37  °C in 
humidified atmosphere of 5% CO2.
Quantitative RT‑PCR
Total RNA from tissue samples was isolated using the 
RNAzol® RT reagent (Molecular Research Centre, 
INC.) according to manufacturer’s instructions. One µg 
of total RNA was reverse-transcribed by random prim-
ers (Promega) and Protoscript II Reverse Transcriptase 
(New England Biolabs) following the manufacturer’s 
protocol. RT-minus reaction that served as a control of 
residual DNA contamination in the RNA sample did 
not contain the Reverse Transcriptase. Both absolute 
and relative qRT-PCR analyses of the synthetized cDNA 
were employed to quantify the mRNA expression of the 
genes of interest (ERVWE1, ERVFRDE1, GCM1, ASCT1, 
ASCT2, HERV-Ws on chromosomes 4 and 21) and RNA 
polymerase II, subunit A (POLR2A), which served for 
normalization as a housekeeping control. MESA GREEN 
qRT-PCR Master Mix Plus for SYBR Assay (Eurogen-
tec) with a CFX1000 cycler and CFX Manager Software 
3.1 (both BioRad) were applied. All reactions were run 
in triplicate and the average Cts were used for quantita-
tion. The negative control contained water instead of 
cDNA. Calibration curves derived from serial ten-fold 
dilutions of the known quantity of ERVWE1, syncytin-1, 
ERVFRDE1, syncytin-2, GCM1, HERV-Ws on chromo-
somes 4 and 21, and POLR2A molecules were used to 
calculate the absolute numbers of mRNA molecules. The 
data were normalized as the percentage of mRNA of the 
POLR2A in the sample. Full-length and spliced forms of 
ERVWE1 and ERVFRDE1 were discriminated by using 
the same forward primers localized in 5′LTR in combi-
nation with the reverse primers localized either in the 
5′UTR region or in the coding sequence of env (Fig. 1). 
The specificity of all primers was thoroughly verified 
by sequencing multiple random clones of the respec-
tive PCR products. To correctly quantify the amount of 
the full-length ERVWE1, ERVFRDE1 and HERV-Ws on 
chromosome 4 and 21 RNAs that do not contain introns 
between the pair of primers, the data obtained from RT-
minus controls were subtracted from the total amount 
measured in the RT-plus sample. In all experiments, the 
RT-minus controls reached less than 5% of RT-plus sam-
ples. Relative quantification was used for the analysis of 
ASCT1 and ASCT2 expression and was also normalized 
to the corresponding POLR2A. For all qRT-PCR analy-
ses, the common protocol was applied: 40 cycles of 95 °C 
15 s, primer annealing 20 s, 72 °C 30 s, and fluorescence 
reading. The sequences of primers and annealing temper-
atures are indicated in Additional file 2: Table S2.
In order to confirm the results normalized to POLR2A, 
we additionally normalized expressions of the full-length 
ERVWE1, spliced syncytin-1, full-length ERVFRDE1 
and spliced syncytin-2 in all samples also to the TATA-
box binding protein (TBP) gene. The calibration curve 
derived from serial ten-fold dilutions of the known quan-
tity of TBP molecules was used to calculate the absolute 
numbers of mRNA molecules. The results were propor-
tional to the POLR2A normalization (see Additional 
file 3: Fig. S1 (A) to (D)) corresponding to the primer effi-
ciency of 93 and 95% for POLR2A and TBP, respectively.
Droplet digital PCR
To analyze the copy number variation and expression of 
different human endogenous retroviruses, we performed 
absolute quantification by means of droplet digital PCR 
(ddPCR). For the copy number variation we used total 
chromosomal DNA, for the expression analysis we used 
the synthetized cDNA. The PCR reaction contained 
ddPCR™ Supermix for Probes and Droplet Generation 
Oil for Probes and was performed by means of QX100™ 
Droplet Digital™ PCR System (all BioRad). The protocol 
for the copy number analysis consisted of: 95 °C 10 min, 
95 °C 30 s–60 °C 60 s—40 cycles. For the qRT-PCR analy-
sis, ddPCR protocol was following: 95  °C 10 min, 95  °C 
30 s–57 °C 30 s–72 °C 30 s—43 cycles. The data were ana-
lyzed with QuantaSoft™ software. All reactions were run 
in duplicate and the average concentrations were used 
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for quantification. The negative control contained water 
instead of DNA or cDNA. For both analyses, the same 
PCR reaction contained two pairs of primers and two 
probes in parallel to quantify the gene of interest and the 
gene used for normalization at the same time. The copy 
number variation of ERVWE1 was normalized according 
to the RPP30 (Ribonuclease P/MRP Subunit P30) copy 
number. The absolute expression of human endogenous 
retrovirus HERV-H was normalized according to the 
POLR2A expression, and respective RT-minus controls 
reaching up to 5% of their RT-plus counterparts were 
subtracted. The specificity of primers and probes was 
verified by sequencing the amplified products. Sequences 
of primers and probes used for ddPCR analysis are indi-
cated in Additional file 2: Table S2.
Chromosomal DNA isolation
Samples of total genomic DNA from the tissues, TCam-
2, and BeWo cell lines were isolated using Proteinase K, 
RNase A, phenol–chloroform extraction and ethanol 
precipitation.
Bisulfite and oxidative bisulfite sequencing
Simple bisulfite treatment does not distinguish between 
5-mC and 5-hmC, and keeps both 5-mCs and 5-hmCs as 
Cs while converting all unmodified Cs into uracils (U). On 
the other hand, oxidative DNA treatment ensures quanti-
tative conversion of 5-hmC bases into 5-fCs. The bisulfite 
treatment of oxidized DNA converts the 5-fCs and the 
non-modified Cs into Us, while only the 5-mCs are kept 
as non-converted Cs. Therefore, to identify the percentage 
of 5-hmC in a specific sequence, the percentage of 5-mC 
obtained after oxidative treatment plus bisulfite sequenc-
ing must be subtracted from the percentage of 5-modi-
fied C obtained after the simple bisulfite treatment. One 
µg of genomic DNA was used for simple bisulfite con-
version or oxidative treatment plus bisulfite conversion 
by means of TrueMethyl® Seq kit (CEGX, Cambridge 
Epigenetix) applied according to the protocol recom-
mended by the manufacturer. Bisulfite-treated DNA was 
amplified by PCR specific for 5′ LTR in a 50-µl reaction 
mixture using ERVWE1-BIS-FW and ERVWE1-BIS-RV 
primers. See Additional file  2: Table S2 for the primer 
sequences. The bisulfite-specific sense primers contained 
thymine and the antisense primers adenine instead of C 
in positions complementary to non-methylable C (i.e., 
C out of CpG dinucleotides). One 50-μl reaction con-
tained: 2 μl of bisulfite/oxidative bisulfite-treated product, 
2.5 mM MgCl2, 2 μg HotStart-IT® Binding Protein (Affy-
metrix), 0.32 μM primers, 2 U Platinum Taq polymerase 
Fig. 1 Schematic illustration of the examined human endogenous retroviruses, ERVWE1, the adjacent endogenous retroelement HERV-H at chro-
mosome 7q21.2, and two HERV-W loci on chromosomes 4 and 21. Human endogenous retrovirus ERVWE1 includes 5′LTR containing the enhancer/
promoter sequence, 3′LTR, an intron of cellular origin located downstream of 5′LTR, the Δgag-Δpol gene and the env gene with an intact open 
reading frame. Two RNA variants of ERVWE1 can be produced (depicted by bold lines): full-length RNA, which includes all three genes mentioned 
above and monocistronic spliced mRNA containing the env gene. The Syncytin-1 protein can be produced only from the spliced form. ERVWE1 
itself integrated into MaLR LTR whose parts are located on both sides of the ERVWE1, Trophoblast-specific enhancer (TSE) located upstream of 
the ERVWE1 5′ LTR contains a GCM1 binding site and is required for placenta-specific expression of ERVWE1. Another retroelement in the close 
proximity of ERVWE1, the human endogenous retrovirus HERV-H, consists of 5′ and 3′ LTR and the gag-pol gene, and is integrated within the LTR9b 
retroelement. In addition, we examined expression of two HERV-W elements on chromosomes 4 and 21. Both contain 5′ and 3′ LTRs, an intron of 
cellular origin located downstream of 5′LTR, the ∆gag-∆pol gene and the ∆env gene. Pairs of primes used for the qRT-PCR analysis are depicted by 
arrows. Length-scale bar indicates 1 kbp. Chromosomal positions assigned according to the genome assembly GRCh38/gh38, December 2013
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(ThermoFisher Scientific) and 0.2 mM dNTPs (Promega). 
The following PCR program was applied: 95  °C 5  min, 
95 °C 50 s–58 °C 2 min–68 °C 1 min 30 s—25 cycles; 95 °C 
45 s–54 °C 2 min–68 °C 1 min 30 s—15 cycles and 68 °C 
10 min. At least three primary PCRs were performed for 
each sample to exclude amplification of one template mol-
ecule. Non-converted DNA did not provide bands. Sev-
eral non-template controls were included in each bisulfite 
PCR reaction. Amplification products were cloned in the 
pGEM-T-EasyVector System (Promega) and sequenced. 
Analysis was performed using the Quma (Quantification 
tool for Methylation Analysis) software (http://quma.cdb.
riken.jp/). Only PCR clones with at least 95% conversion 
of cytosines outside CpGs were taken into account. When 
more converted molecules with identical sequences were 
obtained, only one was used for calculation of the meth-
ylated CpG percentage to minimize the bias originating 
from the preferential amplification of one molecule.
The efficiency of 5-hmC to 5-fC oxidation was controlled 
using the 5-hmC-containing synthetic probe. The cor-
responding region of the ERVWE1 promoter was ampli-
fied by PCR from genomic DNA using the dNTP mix with 
dhmCTP replacing the dCTP (see Additional file 2: Table 
S2 for the primer sequences ERVWE1-nonBIS-FW and 
ERVWE1-nonBIS-RV). The amplified product of 538  bp 
containing 155 5-hmCs was isolated from the agarose gel 
and 100  ng of the 5-hmC-containing fragment was sub-
jected to oxidative bisulfite treatment by means of TrueM-
ethyl® Seq kit (CEGX, Cambridge Epigenetix). Thereafter, 
PCR was performed using the bisulfite-specific ERVWE1 
primers (see Additional file 2: Table S2, primers ERVWE1-
BIS-FW and RV). Amplification products of three pri-
mary PCRs were cloned in the pGEM-T-Easy vector and 
sequenced. Analysis was performed using the Quma 
software and all PCR clones were taken into account 
regardless of the C conversion rate. Overall 5-hmC to U 
conversion levels of 97.9 to 99.3% were observed in indi-
vidual molecules of the oxidation controls indicating effi-
cient oxidation.
Statistical analysis
For statistical analysis of data GraphPad Prism software, 
version 5.04, was used and two-tailed Mann–Whitney 
test was applied. Significance was assigned as follows: **** 
for P-values <0.0001, *** for P-values <0.001, ** for P-val-
ues <0.01, * for P-values <0.05.
Results
Derepression of ERVWE1 transcription in seminoma 
and other GCTs
In order to assess the ERVWE1 expression in the GCTs 
with particular respect to seminomas, we employed qRT-
PCR and quantified the absolute levels of full-length 
ERVWE1 RNA (Fig.  1) in our panel of tumor samples 
and in tumor-matched controls (Additional file  1: Table 
S1). In total, 30 pure seminomas, one scar after the semi-
noma, and 17 non-seminoma GCTs, mostly mixed GCTs, 
were examined.
We observed significantly increased levels of full-
length ERVWE1 RNA in seminomas with median 20% 
of POLR2A in comparison with seminoma-matched 
controls (4% of POLR2A) and non-seminoma GCTs (3% 
of POLR2A, Fig.  2a). Median of the ERVWE1 expres-
sion in seminomas was higher than in the seminoma cell 
line TCam-2 (9% of POLR2A) and was comparable with 
BeWo cells (24% of POLR2A), the fusogenic cell line of 
choriocarcinoma origin (Fig.  2a). ERVWE1 full-length 
RNA levels in the non-seminomas were comparable 
with non-seminoma-matched controls (2% of POLR2A), 
but higher than in the non-GCT testes (1% of POLR2A, 
Fig.  2a). Interestingly, among the non-seminoma GCTs, 
the maximum amount of full-length ERVWE1 RNA 
(404% of POLR2A) was detected in the mixed GCT T43 
consisting of 40% choriocarcinoma, 30% embryonal car-
cinoma and 30% yolk sac tumor components. Two other 
mixed GCTs with superior expression of ERVWE1 con-
tained the seminoma components (T32 with 80% semi-
noma and 20% embryonal carcinoma component, and 
T33 with 60–70% seminoma, 25–30% teratoma, and 15% 
embryonal carcinoma component).
On the other hand, the analyzed samples of endome-
trial carcinomas and lymphomas displayed a signifi-
cantly lower level of full-length ERVWE1 RNA (median 
1 and 10% of POLR2A, respectively) than the seminomas 
(Fig. 2a). No significant differences in ERVWE1 RNA lev-
els were observed between Hodgkin and non-Hodgkin 
lymphomas (median 14 and 5% of POLR2A, respectively, 
Additional file 4: Fig. S2). Unexpectedly, placenta samples 
also displayed a low level of full-length ERVWE1 RNA 
(median 13% of POLR2A, Fig. 2a).
In conclusion, seminomas displayed significantly 
higher levels of non-spliced ERVWE1 RNA in compari-
son with the seminoma-matched controls and also with 
the non-seminomas or endometrial carcinomas and 
lymphomas.
Efficient splicing of ERVWE1 RNA in seminoma
Fusogenic Syncytin-1 can be translated only from spliced 
ERVWE1 env mRNA (Fig.  1). Therefore, we quantified 
the absolute levels of spliced syncytin-1 mRNA in GCTs 
employing the splice-specific qRT-PCR described previ-
ously [13].
We detected a very high level of syncytin-1 mRNA in 
seminomas (median 49% of POLR2A), BeWo cells (80% 
of POLR2A), and particularly placenta (median 820% 
of POLR2A, Fig.  2b). BeWo cells and placentas validated 
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Fig. 2 Expression analysis of the ERVWE1 locus. Expression from the ERVWE1 locus was analyzed by qRT-PCR in the panel of tumor samples. Both 
the full-length RNA (a) and spliced syncytin-1 mRNA (b) forms were quantified. All the data were normalized to % POLR2A. Each sample is repre-
sented by a dot and was measured as a technical triplicate. In each column, median with interquartile range is depicted. Splicing efficiency is shown 
in (c). Each sample is depicted by a dot which represents the ratio of spliced syncytin-1 mRNA to the sum of full-length RNA and spliced mRNA in 
the analyzed sample. Significance was assigned as follows: **** for P-values <0.0001, *** for P-values <0.0001, ** for P-values <0.01, * for P-values 
<0.05
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our splice-specific qRT-PCR assay because Syncytin-1 
has been shown to be placenta-specific [3] and Syncytin-
1-mediated cell-to-cell fusion was described in BeWo cells. 
Syncytin-1 mRNA expression in TCam-2 cell line reached 
32% of POLR2A. The level of syncytin-1 mRNA in semi-
nomas was significantly higher than in the seminoma-
matched controls (5% of POLR2A) and non-seminoma 
GCTs (2% of POLR2A, Fig.  2b). Importantly, two mixed 
GCTs with the most abundant expression of full-length 
ERVWE1 RNA, T33 and T32, also displayed high levels of 
spliced syncytin-1 mRNA. Both tumors contained a large 
proportion of seminoma. In contrast, T43 with the high-
est level of full-length ERVWE1 RNA displayed only a low 
level of spliced syncytin-1 mRNA (3% of POLR2A). This 
mixed GCT lacked any seminoma component. Only neg-
ligible levels of the spliced syncytin-1 mRNA were found 
in the non-GCT testes, endometrial carcinomas and lym-
phomas (Fig. 2b). No significant differences in syncytin-1 
mRNA levels were observed between Hodgkin and non-
Hodgkin lymphomas (Additional file 4: Fig. S2).
We further determined the splicing efficiency as a ratio 
of spliced syncytin-1 mRNA to the sum of spliced and 
full-length ERVWE1 RNA in the same sample. Despite 
significantly higher amounts of ERVWE1 RNA and syn-
cytin-1 mRNA in seminomas versus seminoma-matched 
controls, the efficiency of splicing in seminomas and 
seminoma-matched controls did not differ significantly 
(Fig.  2c). However, the efficiency of splicing in semino-
mas (median 0.63) was significantly higher in comparison 
with the non-seminomas (median 0.34, Fig. 2c). The 0.99, 
0.79 and 0.77 splicing efficiencies were found in placen-
tas, TCam-2 and BeWo cell lines, respectively. On the 
other hand, the lowest efficiency of splicing was detected 
in the non-GCT testes (median 0.13), endometrial carci-
nomas (median 0.21) and lymphomas (median 0.00).
Our results showed that, similarly to the non-spliced 
ERVWE1 RNA, the levels of the spliced syncytin-1 
mRNA were upregulated in seminomas over the semi-
noma-matched controls and, again, over the non-semino-
mas. In seminomas, the ERVWE1 RNA was transcribed 
at high intensity, and the majority of this RNA was effi-
ciently spliced into the syncytin-1 mRNA.
Derepression of ERVFRDE1 expression in seminoma
ERVFRDE1 is the second endogenous retrovirus encod-
ing placenta-specific, fusogenic glycoprotein Syncy-
tin-2. Therefore, we examined the expression of both 
full-length and spliced ERVFRDE1 RNAs in our panel of 
seminomas and non-seminoma GCTs.
The level of full-length ERVFRDE1 RNA in semi-
nomas, placentas, TCam-2 and BeWo cells was low 
(median 3, 4, 5 and 4% of POLR2A, respectively), but 
significantly higher than in seminoma-matched controls 
and, importantly, non-seminoma GCTs (1.5 and 1.2% of 
POLR2A, respectively, Fig.  3a). Similarly to ERVWE1, 
the levels of spliced syncytin-2 mRNA in seminomas 
(median 12% of POLR2A) were higher than in non-sem-
inoma GCTs (median 7% of POLR2A) and the non-GCT 
controls (median 5% of POLR2A, Fig. 3b). In contrast to 
ERVWE1, the levels of spliced syncytin-2 mRNA in semi-
nomas were not elevated over the seminoma-matched 
controls (median 11% POLR2A, Fig.  3b). The levels of 
ERVFRDE1 RNA in Hodgkin and non-Hodgkin lym-
phomas were similar, but the levels of spliced syncytin-2 
mRNA were higher in the non-Hodgkin lymphomas 
(median 12% of POLR2A) than in the Hodgkin lympho-
mas (median 6% of POLR2A, Additional file 4: Fig. S2). 
Placentas, that served as a positive control, showed the 
highest expression of spliced syncytin-2 mRNA (median 
328% of POLR2A, Fig. 3b).
We further compared the efficiency of ERVFRDE1 
splicing and found no significant differences between 
the seminomas and non-seminomas (Fig. 3c). Neverthe-
less, the efficiency of ERVFRDE1 splicing was lower in 
seminomas than in the seminoma-matched controls or 
the non-GCT testes, endometrial carcinomas or lym-
phomas (Fig. 3c). As in the case of ERVWE1, placentas 
displayed very high efficiency of ERVFRDE1 RNA splic-
ing (median 0.99). Interestingly, the splicing efficiency 
of ERVFRDE1 RNA in both seminomas and non-sem-
inomas was higher than that of ERVWE1 RNA (Addi-
tional file 5: Fig. S3).
Overall, elevated levels of the full-length ERVFRDE1 
RNA and spliced syncytin-2 mRNA were found in semi-
nomas in comparison to non-seminoma GCTs. When 
comparing the levels of the full-length and spliced forms 
of ERVWE1 versus ERVFRDE1 in the non-seminomas, 
the spliced syncytin-2 mRNA was slightly elevated over 
the spliced syncytin-1 mRNA (P  >  0.05). On the other 
hand, in the seminomas, the levels of both non-spliced 
ERVWE1 RNA and spliced syncytin-1 mRNA were sig-
nificantly higher than the levels of the non-spliced ERV-
FRDE1 RNA and spliced syncytin-2 mRNA, respectively 
(P > 0.0001 in both cases, Additional file 6: Fig. S4A and 
B). These results underscore the significance of ERVWE1 
and syncytin-1 overexpression in seminomas.
ASCT1 and ASCT2, the receptors of Syncytin‑1, are not 
overexpressed in GCTs
The fusogenic capacity of Syncytin-1 requires interac-
tion with its specific receptors ASCT1 and ASCT2. To 
assess the fusogenic potential of GCTs, we quantified the 
expression of ASCT1 and ASCT2 mRNA in our panel of 
seminomas and non-seminomas and compared it with 
the BeWo cell line and placenta samples, both charac-
terized by efficient cell-to-cell fusion and Syncytin-1 
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Fig. 3 Expression analysis of the ERVFRDE1 locus. Expression from the ERVFRDE1 locus was analyzed by qRT-PCR in the panel of tumor samples. 
Both the full-length RNA (a) and spliced syncytin-2 mRNA (b) forms were quantified. All the data were normalized to % POLR2A. Each sample is 
represented by a dot and was measured as a technical triplicate. In each column, median with interquartile range is depicted. Splicing efficiency is 
shown in panel (c). Each sample is depicted by a dot which represents the ratio of spliced mRNA to the sum of full-length RNA and spliced mRNA 
in the analyzed sample. Significance was assigned as follows: **** for P-values <0.0001, *** for P-values <0.001, ** for P-values <0.01, * for P-values 
<0.05
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expression. The expression of both receptors was quanti-
fied relatively to their expression in the TCam-2 cell line 
that displayed comparable and relatively high expression 
of both receptors (Fig. 4a, b). The relative levels of ASCT1 
and ASCT2 mRNA in seminomas were low (median 0.34 
and 0.27 of TCam-2 expression, respectively), and no sig-
nificant difference from the seminoma-matched controls 
or non-seminomas was detected (Fig. 4a, b). Nevertheless, 
seminomas showed higher expression of ASCT2 than the 
non-GCT controls (median 0.13 of TCam-2 expression, 
Fig.  4b). Non-seminomas even displayed lower levels of 
ASCT1 mRNA than the matched controls (Fig. 4a). Pla-
centas displayed ASCT1 mRNA levels comparable with 
seminomas (median 0.4 of TCam-2 expression, Fig.  4a) 
but the ASCT2 mRNA levels were lower than in the 
seminomas (median 0.1 of TCam-2 expression, Fig.  4b). 
ASCT1 mRNA expression in the BeWo cell line was lower 
than in placentas (0.2 of TCam-2 expression, Fig. 4a) but 
the ASCT2 expression was comparable with the TCam-2 
cell line (1.2 of TCam-2 expression, Fig. 4b). Our results 
showed that seminomas do not express elevated levels of 
ASCT1 or ASCT2 mRNA over the matched controls or 
over the non-seminomas.
Copy number of ERVWE1 in seminoma
Next, in order to determine the mechanism of ERVWE1 
overexpression in seminomas, we quantified the 
ERVWE1 copy number using droplet-digital PCR. We 
examined the genomic DNA of five seminomas and four 
seminoma-matched controls, six non-seminomas and 
the corresponding matched controls, one non-GCT tes-
tis, one lymphoma, one endometrial carcinoma and one 
placenta sample.
The analyzed tumor-matched controls, the sample of 
non-GCT testis, and the sample of placenta did not show 
any abnormalities in the ERVWE1 copy number. On the 
other hand, seminomas displayed ERVWE1 copy num-
bers varying between 0.97 and 1.78 per haploid genome 
(Fig. 5). Despite higher levels of full-length ERVWE1 and 
spliced syncytin-1 mRNA expression in seminomas over 
the non-seminomas (Fig. 2), the ERVWE1 copy number 
in both types of GCTs did not differ (median 1.34 copies 
per haploid genome in both cases, Fig. 5). Furthermore, 
the ERVWE1 copy number in seminomas was not signifi-
cantly higher in comparison with the seminoma-matched 
controls. On the other hand, the ERVWE1 copy number 
in the non-seminomas was significantly increased over 
the matched controls (Fig.  5). Moreover, the increased 
ERVWE1 copy number in individually analyzed GCTs 
mostly did not correspond to the ERVWE1 expression 
levels in these tumors, as documented e.g. for T3 and 
T36 tumor samples (Additional file 7: Fig. S5).
In conclusion, we detected increased ERVWE1 copy 
numbers in several GCTs. However, the higher ERVWE1 
copy number did not correspond to the expression level 
of ERVWE1 RNA or syncytin-1 mRNA. Therefore, the 
increased ERVWE1 copy number was not sufficient to 
explain ERVWE1 derepression in GCTs.
GCM1 is not overexpressed in GCTs or seminomas
Transcription factor GCM1 is known to stimulate 
ERVWE1 transcription. We explored the absolute levels 
Fig. 4 Human ASCT1 and ASCT2 mRNA expression analysis. The 
human ASCT1 (a) and ASCT2 (b) mRNA levels were measured by 
qRT-PCR. All the data were normalized to the expression in TCam-2 
cells. Each sample is represented by a dot and was measured as a 
technical triplicate. In each column, median with interquartile range 
is depicted. Significance was assigned as follows: ** for P-values <0.01, 
* for P-values <0.05
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of GCM1 in the GCTs using qRT-PCR. In the panel of 
randomly selected seminomas and non-seminoma 
GCTs, we detected similarly low levels of GCM1 expres-
sion (median 0.3350% POLR2A and 0.7493% POLR2A, 
respectively, Fig.  6) that was not increased over the 
tumor-matched controls and non-GCT testes. As 
expected, high levels of GCM1 mRNA were found only 
in the placentas (median 91% POLR2A) and BeWo cell 
line (57% POLR2A, Fig. 6). We concluded that high levels 
of ERVWE1 expression in seminomas were not mediated 
by the GCM1 transcription factor.
Low level of CpG methylation and hydroxymethylation 
of ERVWE1 promoter in seminoma
We have shown previously that DNA hypermethylation 
suppresses transcription from the ERVWE1 promoter 
in non-placental tissues [12, 13] and we assume that 
demethylation is a prerequisite for ERVWE1 derepres-
sion. Recently, we have described elevated expression of 
TET enzymes in GCTs, particularly seminomas [30]. We 
therefore explored the levels of 5-mC and 5-hmC at the 
ERVWE1 promoter using bisulfite sequencing and oxi-
dative bisulfite modification. The combination of these 
techniques allows discrimination between 5-mC and 
5-hmC.
In accordance with our assumption, we found signifi-
cantly decreased levels of 5-mCpG at the ERVWE1 pro-
moter in all analyzed seminoma samples in comparison 
with the seminoma-matched controls (Fig.  7). The 
ERVWE1 promoter in seminoma T6, where the matched 
control was not available, was extremely hypomethyl-
ated (6% of mCpG, Fig. 7). No significant difference was 
observed between the results of bisulfite and oxidative 
bisulfite sequencing despite the efficient oxidative treat-
ment (Additional file 8: Fig. S6). This indicates that very 
low or undetectable levels of 5-hmCpG were present at 
the ERVWE1 promoter in all seminoma samples at the 
time of analysis (Fig.  7; Table  1). The methylation pat-
terns of seminomas T3, T4 and T6 showed either fully 
methylated or demethylated molecules (Additional 
file 9: Fig. S7). The analyzed lymphoma sample displayed 
hypermethylation of the ERVWE1 promoter and unde-
tectable levels of 5-hmCpG (Fig. 7; Table 1). As expected, 
placenta and BeWo cell line contained a hypomethylated 
promoter of ERVWE1. Again, the 5-hmCpG was not 
detected (Fig. 7; Table 1).
The results showed that 5-hmC levels at the ERVWE1 
promoter in the GCTs were undetectable despite the 
high expression of TET1-3 mRNAs [30]. These findings 
pointed out the importance of 5-hmC turnover kinetics. 
Importantly, seminomas displayed low levels of 5-mC 
modification at the ERVWE1 promoter that allowed 
transcription from the ERVWE1 promoter to occur.
Fig. 5 ERVWE1 copy number analysis. The ERVWE1 copy number 
was measured by ddPCR in the selected panel of human tumors. The 
copies of ERVWE1 were measured relatively to copies of the reference 
gene RPP30. Each sample is represented by a dot. The red spotted line 
schematically represents one copy per haploid genome. Each sample 
was measured in technical duplicate. Significance was assigned as 
follows: ** for P-values <0.01
Fig. 6 Human GCM1 mRNA expression analysis. The human GCM1 
mRNA level was measured by qRT-PCR. All the data were normalized 
to % POLR2A expression. Each sample is represented by a dot and 
was measured as a technical triplicate. In each column, median with 
interquartile range is depicted. Significance was assigned as follows: 
*** for P-values <0.001, ** for P-values <0.01
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Fig. 7 CpG methylation and hydroxymethylation profiles of the ERVWE1 promoter in selected samples. To analyze CpG modifications of the 
ERVWE1 promoter (5′LTR), bisulfite together with oxidative bisulfite sequencing were applied. Results of the bisulfite sequencing (5-mC + 5-hmC) 
are shown in the left part of the picture, results of the oxidative bisulfite sequencing (5-mC) in the right part of the picture. Analysis of the promoter 
molecules is shown as a linear array of open circles representing non-modified CpG residues and closed circles representing methylated or hydroxy-
methylated CpG residues. Each line represents one sequenced molecule of the 5′ LTR. The mean percentage of modified CpGs is presented for 
each sample. Schematic representation of the CpG dinucleotide distribution in the ERVWE1 promoter together with primers used for the analysis is 
shown at the bottom. Significance was assigned as follows: *** for P-values <0.001, ** for P-values <0.01
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Expression of additional endogenous retroviruses in GCTs
Finally, to assess whether derepression of endogenous 
retroviruses in seminomas is a more common phenome-
non or whether it is ERVWE1-specific, we explored tran-
scription of the HERV-H endogenous retroviral element 
co-localized with ERVWE1 on chromosome 7 (Fig.  1), 
in randomly selected samples of GCTs using ddPCR. 
We further quantified RNA levels of two additional non-
pseudogenic HERV-W elements, localized on chromo-
somes 4 and 21 (Fig.  1), using the RT-qPCR approach. 
We selected these HERV-W loci because they were pre-
viously found overexpressed in testicular tumors using 
RNA microarray analysis [14].
Both analyzed endogenous HERV-W elements showed 
elevated expression in seminomas (median 4 and 8% 
of POLR2A for HERV-W on chromosomes 4 and 21, 
respectively) over the seminoma-matched controls and 
the non-seminoma GCTs (Fig.  8a, b). RNA transcribed 
from the HERV-W elements on chromosomes 4 and 21 
further showed higher levels in seminomas in compari-
son with non-GCT testes, endometrial carcinomas, and 
lymphomas. Non-seminomas displayed higher levels of 
HERV-W on chromosomes 4 and 21 only over the non-
GCT testes. The levels of HERV-H RNA were not signifi-
cantly different in the sets of seminomas (median 1.8% of 
POLR2A), non-seminoma GCTs (1.2% of POLR2A), the 
respective tumor-matched controls (2.3% POLR2A), and 
non-GCT testes (1.5% of POLR2A, Fig. 8c). Interestingly, 
placenta samples efficiently silenced transcription of both 
HERV-W and HERV-H element (Fig. 8).
In conclusion, the expression of HERV-H located 
upstream to ERVWE1 and two additional HERV-W 
loci do not reach by far the levels of either full-length or 
spliced ERVWE1 RNA in seminomas (compare Figs. 2a, 
b and 8, see also the Additional file  6: Fig. S4). These 
results indicate that ERVWE1 is regulated independently 
of the other analyzed endogenous elements located either 
in close proximity to ERVWE1 or in remote genomic 
regions.
Discussion
In this study, we have described elevated syncytin-1 
mRNA expression in seminomas and mixed GCTs with 
a seminoma component. Our previous studies showed 
that ERVWE1 is suppressed by epigenetic mechanisms 
in non-placental tissues [12, 13]. This is further corrobo-
rated in this study showing the importance of ERVWE1 
5′ LTR hypomethylation for its expression. Another 
mechanism indispensable for this aberrant upregula-
tion in the seminoma was efficient splicing of ERVWE1 
RNA providing the template for syncytin-1 translation. 
In summary, we show that the full-length and particu-
larly the spliced form of ERVWE1 RNA is a hallmark of 
seminoma.
Although there are many examples of aberrant HERV 
expression in cancer (reviewed in [38]), ERVWE1 and 
ERVFRDE1 are exceptional in several aspects: expres-
sion of their envelope glycoproteins could have func-
tional consequences for the cell and is, therefore, tightly 
controlled in non-placental tissues [11–14]. Second, only 
spliced transcripts can be used for envelope glycopro-
tein translation, which adds a further step to the com-
plex control mechanisms [13]. Splicing efficiency has not 
been studied at all in cancer-specific aberrant expression 
of other HERV families. Third, the trophoblastic expres-
sion of ERVWE1 is controlled from a juxtaposed troph-
oblast-specific enhancer localized in MaLR LTR [9] and 
requires stimulation by certain tissue-specific transcrip-
tion factors, such as GCM1 [10, 39], whose activity could 
be studied in germ line tumors. In neither type of tumors 
described in this study, we observed GCM1 expression 
comparable with placenta or BeWo cells, which points to 
the critical importance of promoter demethylation as a 
prerequisite for ERVWE1 transcriptional de-repression.
We did not observe elevated expression of ERVWE1 
RNA in endometrial carcinomas as it was reported in 
[17]. Our collection of endometrial cancers was less 
extensive, we examined only seven endometrial carci-
nomas, including six endometrioid and one clear cell 
Table 1 Percentage of  5-mCpG and  5-hmCpG on  the 
ERVWE1 promoter
a The percentage of total 5-mCpG + 5-hmCpG modification of the ERVWE1 
promoter was obtained after the conventional bisulfite sequencing
b The percentage of 5-mCpG modification of the ERVWE1 promoter was 
obtained after the oxidative modification of the bisulfite sequencing
c The percentage of 5-hmCpG modification of the ERVWE1 promoter was 
obtained by subtracting the percentage of 5-mCpG from the percentage of total 
modified CpG. Such subtraction produced negative values in several cases. The 
P value calculated using the Mann–Whitney two-tailed test was >0.05, i.e. non-














T3 (seminoma) 6 7 −1
T3-matched control 52 49 3
T4 (seminoma) 29 27 2
T4-matched control 93 83 10
T5 (seminoma) 44 48 −4
T5-matched control 86 87 −1
T6 (seminoma) 6 8 −2
T59 (lymphoma) 88 91 −3
Placenta 26 23 3
BeWo 0 1 −1
TCam-2 66 66 0
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endometrial carcinomas of endometrial and myome-
trial localization, all in stage T1. Lymphomas showed 
slightly elevated levels of the full-length ERVWE1 RNA 
but only the background levels of the spliced syncytin-1 
mRNA indicating very low splicing efficiency of the 
ERVWE1 RNA (Fig. 2). Comparison of the Hodgkin and 
Fig. 8 Expression of additional HERV-Ws and HERV-H in the panel of selected samples. Expression of HERV-W on chromosome 4 (a), HERV-W on 
chromosome 21 (b), and HERV-H adjacent to ERVWE1 (c), was analyzed in the panel of selected samples. All the data were normalized to % POLR2A. 
Each sample is represented by a dot and was measured as a technical triplicate. In each column, median with interquartile range is depicted. Signifi-
cance was assigned as follows: **** for P-values <0.0001, *** for P-values <0.001, ** for P-values <0.01, * for P-values <0.05
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non-Hodgkin lymphomas is shown in Additional file  4: 
Fig. S2.
The fusogenic capacity of Syncytin-1 and Syncytin-2 
imposes the idea of syncytial activity in germ cell tumors 
with increased levels of spliced syncytin mRNA. We 
observed syncytial cells with low numbers of nuclei in 
the seminoma cell line TCam-2 as well as multinucle-
ated syncytia in the BeWo cell line correlating well with 
the high expression of Syncytin-1 receptors, ASCT1 
and ASTC2 in these cell lines. On the other hand, we 
did not observe systematic overexpression of ASCT2 in 
the GCTs. However, both seminomatous and, to a lesser 
extent, mixed GCTs are known to contain neoplastic 
giant cells of various types including mono- or multinu-
clear elements [40] with increased hCG expression [41]. 
It remains to be studied whether the presence of syncytia 
in GCTs requires syncytin-1 and -2 expression.
Interestingly, the methylation patterns of ERVWE1 
promoter in several analyzed seminomas and placentas 
were bimodal showing either completely demethylated 
molecules or heavily methylated molecules. Only the 
T5 seminoma displayed a patchy methylation pattern of 
CpGs (Additional file 9: Fig. S7). This observation could 
underline the importance of promoter DNA demeth-
ylation for transcriptional derepression. A similar “all or 
nothing” pattern has also been observed in promoters of 
latent or activated HIV-1 proviruses [42]. Alternatively, 
different cellular types present in the samples could pro-
duce contrasting methylation patterns. The technical 
procedure of bisulfite sequencing and analysis used in 
this study was designed to avoid biased results by pref-
erential amplification of single molecules and already 
adjusted for extremely rare targets [42].
In our recent work [30], we documented the hypo-
methylated genome of seminomas and associated this 
hypomethylation with strikingly elevated levels of TET 
dioxygenases, enzymes with DNA demethylase activi-
ties. Any decrease in DNA methylation affects particu-
larly the repetitive part of the genome, as up to 90% of 
methylated CpGs are found in repetitive elements includ-
ing the endogenous retroviruses [43]. Accordingly, there 
are reports on activation of HERVs and retrotranspo-
sons in 5-azacytidine-treated cells [44–46], embryonic 
stem cells [47], and induced pluripotent stem cells [48, 
49]. ERVWE1, and to a lesser extent ERVFRDE1 dere-
pression could be the direct consequence of the genome 
hypomethylation in seminoma cells. This, however, does 
not apply generally to all HERVs, and other proviral cop-
ies localized either in close proximity to ERVWE1 or on 
chromosomes 4 and 21 are not efficiently derepressed.
There are several reports of HERV-K expression in 
GCTs (e.g. [39]) and inducible expression of HERV-
K rec gene in mice led to a disturbance of germ cell 
development reminiscent of early seminoma [40]. 
Genome-wide comparison of HERV expression in tes-
ticular cancer and normal testicular tissue has been done 
using copy-specific microarray and several HERV cop-
ies of families E, H, K, and W were found to be differen-
tially expressed in testicular tumors. The expression of 
six HERV-W copies including ERVWE1 was confirmed 
by quantitative RT-PCR and the prevalence of spliced 
ERVWE1 transcripts was demonstrated. In comparison to 
non-testicular tumors and control healthy tissues, normal 
testicular tissue was not exceptional and expressed several 
ubiquitously represented HERV-E, H, and K copies.
Our finding of TET1 overexpression in seminomas [30] 
implicates the role of 5-hmC in transcriptional derepres-
sion. We, however, observed a very low or undetectable 
level of 5-hmC at the ERVWE1 promoter in seminomas 
examined in this study. Although unexpected, this pau-
city of 5-hmC is not at odds with previous reports. E.g., 
5-hmC was detectable in early human PGCs but get 
gradually depleted later on [29]. The genic regions in 
the human PGCs showed a low but significant levels of 
5-hmC whereas the retroelements showed very low levels 
of 5-hmC [28]. Because seminoma maintains multiple fea-
tures of PGCs, this differential 5-hmC distribution could 
explain also the lack of 5-hmC on the ERVWE1 promoter.
The ERVFRDE1 expression was always lower than 
that of ERVWE1 resembling the low ERVFRDE1 level in 
placenta and BeWo cells (this study and [11]). Also, the 
level of DNA methylation at ERVFRDE1 5′LTR in healthy 
matched controls was rather low in comparison with 
ERVWE1 [13, 14]. On the other hand, splicing of ERV-
FRDE1 RNA was quite efficient despite low expression 
levels. Further research of the ERVFRDE1 promoter epi-
genetic status in the context of its transcriptional activa-
tion would improve our understanding of Syncytin-1 and 
Syncytin-2 contribution to cell-to-cell fusion.
Conclusions
In summary, we analyzed ERVWE1 and ERVFRDE1 
expression and splicing in a wide and well character-
ized set of germ cell tumors. Particularly, we correlated 
the ERVWE1 expression, low CpG methylation and, for 
the first time, also low CpG hydroxymethylation status 
of the ERVWE1 promoter with the whole genome hypo-
methylation phenotype of seminoma. We propose the 
spliced syncytin-1 expression as a marker of seminoma 
or seminomatous component of non-seminoma GCTs. 
As seminoma and non-seminoma treatments differ dia-
metrically, we assume that detection of the spliced syncy-
tin-1 mRNA could be useful for differential diagnosis and 
individualized therapy of GCTs. The elevated ERVWE1 
expression without significantly increased copy number 
or increased level of GCM underscores the importance 
Page 15 of 17Benešová et al. Retrovirology  (2017) 14:20 
of epigenetic control of HERV-Ws. Identification of other 
HERV loci transcriptionally active in different types of 
GCTs would improve our understanding of endogenous 
retrovirus regulation.
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represents the efficiency of splicing in the analyzed sample. Median with 
interquartile range is depicted. Significance was assigned as follows: **** 
for P-values < 0.0001, *** for P-values <0.001.
Additional file 6: Figure S4. Comparison of the expression from 
ERVWE1, ERVFRDE1, HERV-W chromosome 4, HERV-W chromosome 21, 
and HERV-H chromosome 7 in seminomas and non-seminomas. Data 
from RT-qPCR analysis (Figs. 2, 3, and 8) were pooled for comparison of 
the expression from examined endogenous retroviral loci in seminomas 
(A) and non-seminomas (B). Each sample is represented by a dot and 
was measured as a technical triplicate. In each column, median with 
interquartile range is depicted. Significance was assigned as follows: **** 
for P-values <0.0001, ** for P-values <0.01, * for P-values <0.05.
Additional file 7: Figure S5. ERVWE1 copy number analysis in individual 
analyzed GCTs (A), and full-length ERVWE1 RNA and spliced syncytin-1 
mRNA expression in individual GCTs (B). (A) The ERVWE1 copy number 
was measured by ddPCR in the selected panel of GCTs. T2 to T6 tumors 
are seminomas, T34 to T36, T41, and T42 GCTs are non-seminomas. The 
copies of ERVWE1 were measured relatively to the copies of the reference 
gene RPP30. Each sample is represented by a dot, black dots represent 
tumor samples, grey dots respective tumor-matched controls. The red 
spotted line schematically represents one copy per haploid genome. Each 
sample was measured in technical duplicate. (B) The expression from the 
ERVWE1 locus in the same panel of samples is depicted. For each sample, 
the levels of both full-length ERVWE1 RNA (white columns) and spliced 
syncytin-1 mRNA (black columns) are shown. The data are presented as 
the mean  ±  SD of technical triplicates. All the data were taken from the 
expression analysis of the ERVWE1 locus (Fig. 2).
Additional file 8: Figure S6. Control of oxidation efficiency at 5-hmC. 
The same region of the ERVWE1 promoter that was analyzed for 5-mC and 
5-hmC modifications was amplified by PCR from genomic DNA employ-
ing the modified dNTP mix that contained dhmCTP instead of dCTP. The 
amplified product of 538 bp containing 155 5-hmCs was isolated from the 
agarose gel and 100 ng of the 5-hmC-containing fragment was subjected 
to oxidative bisulfite treatment. Thereafter, PCR was performed using the 
bisulfite-specific ERVWE1 primers (see Additional file 2: Table S2, primers 
ERVWE1-BIS-FW and RV). Amplification products of three primary PCRs 
were cloned in the pGEM-T-Easy vector and sequenced. Analysis was 
performed using the Quma software and all PCR clones were taken into 
account regardless of the C conversion rate. Overall 5-hmC to U conver-
sion levels of 97.9–99.3% were observed in individual molecules of the 
oxidation controls indicating effective oxidation. Only the Cs in the CpG 
context are depicted: efficient oxidation of the 5-hmC to the 5-fC and sub-
sequent bisulfite conversion is represented as an open circle while non-
efficient oxidation plus bisulfite conversion of the 5-hmC is represented 
graphically as black circle. Two separately performed replicates are shown.
Additional file 9: Figure S7. Distribution of 5′ LTR molecules according 
to the proportion of methylated CpGs. Seminomas T3, T4, T5, T6, respec-
tive matched controls (when available), placenta sample, TCam-2 cell line, 
and lymphoma T59 are depicted. The total counts of methylated CpGs 
per molecule are shown on the Y-axis. The percentage of the respective 
molecules is shown on the X-axis.
Page 16 of 17Benešová et al. Retrovirology  (2017) 14:20 
EK-VP/06/2012. Each patient provided informed written consent to participate 
in this study.
Funding
This work was supported by Grant No. 13-3700S awarded by the Czech Science 
Foundation to JH and Grant No. NT14601-3/2013 awarded by Grant Agency 
of Ministry of Health of the Czech Republic to JH and ZV. The work was also 
institutionally supported by RVO: 68378050 and the research project PRVOUK—
Oncology P27, awarded by Charles University in Prague to ZV, PK and AS.
Received: 21 November 2016   Accepted: 3 March 2017
References
 1. Blaise S, de Parseval N, Benit L, Heidmann T. Genomewide screening for 
fusogenic human endogenous retrovirus envelopes identifies syncytin 
2, a gene conserved on primate evolution. Proc Natl Acad Sci USA. 
2003;100(22):13013–8.
 2. Frendo JL, Olivier D, Cheynet V, Blond JL, Bouton O, Vidaud M, et al. Direct 
involvement of HERV-W Env glycoprotein in human trophoblast cell 
fusion and differentiation. Mol Cell Biol. 2003;23(10):3566–74.
 3. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, et al. Syncytin is a cap-
tive retroviral envelope protein involved in human placental morphogen-
esis. Nature. 2000;403(6771):785–9.
 4. Moller AMJ, Delaisse J-M, Soe K. Osteoclast fusion: time-lapse reveals 
involvement of CD47 and syncytin-1 at different stages of nuclearity.  
J Cell Physiol. 2016;232(6):1396–140.
 5. Lavillette D, Marin M, Ruggieri A, Mallet F, Cosset FL, Kabat D. The 
envelope glycoprotein of human endogenous retrovirus type W uses a 
divergent family of amino acid transporters/cell surface receptors. J Virol. 
2002;76(13):6442–52.
 6. Marin M, Lavillette D, Kelly SM, Kabat D. N-linked glycosylation and 
sequence changes in a critical negative control region of the ASCT1 and 
ASCT2 neutral amino acid transporters determine their retroviral receptor 
functions. J Virol. 2003;77(5):2936–45.
 7. Grandi N, Cadeddu M, Blomberg J, Tramontano E. Contribution of type W 
human endogenous retroviruses to the human genome: characterization 
of HERV-W proviral insertions and processed pseudogenes. Retrovirology. 
2016;13(1):67.
 8. Pavlicek A, Paces J, Elleder D, Hejnar J. Processed pseudogenes of human 
endogenous retroviruses generated by LINEs: their integration, stability, 
and distribution. Genome Res. 2002;12(3):391–9.
 9. Prudhomme S, Oriol G, Mallet F. A retroviral promoter and a cellular 
enhancer define a bipartite element which controls env ERVWE1 placen-
tal expression. J Virol. 2004;78(22):12157–68.
 10. Yu C, Shen K, Lin M, Chen P, Lin C, Chang GD, et al. GCMa regu-
lates the syncytin-mediated trophoblastic fusion. J Biol Chem. 
2002;277(51):50062–8.
 11. Gimenez J, Montgiraud C, Oriol G, Pichon JP, Ruel K, Tsatsaris V, et al. Com-
parative methylation of ERVWE1/syncytin-1 and other human endog-
enous retrovirus LTRs in placenta tissues. DNA Res. 2009;16(4):195–211.
 12. Matouskova M, Blazkova J, Pajer P, Pavlicek A, Hejnar J. CpG methylation 
suppresses transcriptional activity of human syncytin-1 in non-placental 
tissues. Exp Cell Res. 2006;312(7):1011–20.
 13. Trejbalova K, Blazkova J, Matouskova M, Kucerova D, Pecnova L, Vernerova 
Z, et al. Epigenetic regulation of transcription and splicing of syncyt-
ins, fusogenic glycoproteins of retroviral origin. Nucleic Acids Res. 
2011;39(20):8728–39.
 14. Gimenez J, Montgiraud C, Pichon JP, Bonnaud B, Arsac M, Ruel K, et al. 
Custom human endogenous retroviruses dedicated microarray identifies 
self-induced HERV-W family elements reactivated in testicular cancer 
upon methylation control. Nucleic Acids Res. 2010;38(7):2229–46.
 15. Vargas A, Moreau J, Landry S, LeBellego F, Toufaily C, Rassart E, et al. Syn-
cytin-2 plays an important role in the fusion of human trophoblast cells. J 
Mol Biol. 2009;392(2):301–18.
 16. Liang CY, Wang LJ, Chen CP, Chen LF, Chen YH, Chen HW. GCM1 regula-
tion of the expression of syncytin 2 and its cognate receptor MFSD2A in 
human placenta. Biol Reprod. 2010;83(3):387–95.
 17. Strissel PL, Ruebner M, Thiel F, Wachter D, Ekici AB, Wolf F, et al. Reactiva-
tion of codogenic endogenous retroviral (ERV) envelope genes in human 
endometrial carcinoma and prestages: emergence of new molecular 
targets. Oncotarget. 2012;3(10):1204–19.
 18. Strick R, Ackermann S, Langbein M, Swiatek J, Schubert SW, Hashemol-
hosseini S, et al. Proliferation and cell-cell fusion of endometrial carci-
noma are induced by the human endogenous retroviral syncytin-1 and 
regulated by TGF-beta. J Mol Med. 2007;85(1):23–38.
 19. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO 
classification of tumours of the urinary system and male genital organs-
part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
 20. Almstrup K, Nielsen JE, Mlynarska O, Jansen MT, Jorgensen A, Skakkebaek 
NE, et al. Carcinoma in situ testis displays permissive chromatin modifica-
tions similar to immature foetal germ cells. Br J Cancer. 2010;103(8):1269–76.
 21. Kristensen DG, Nielsen JE, Jorgensen A, Skakkebaek NE, Rajpert-De Meyts 
E, Almstrup K. Evidence that active demethylation mechanisms maintain 
the genome of carcinoma in situ cells hypomethylated in the adult testis. 
Br J Cancer. 2014;110(3):668–78.
 22. Looijenga LH, Gillis AJ, van Gurp RJ, Verkerk AJ, Oosterhuis JW. X inactiva-
tion in human testicular tumors. XIST expression and androgen receptor 
methylation status. Am J Pathol. 1997;151(2):581–90.
 23. Netto GJ, Nakai Y, Nakayama M, Jadallah S, Toubaji A, Nonomura N, et al. 
Global DNA hypomethylation in intratubular germ cell neoplasia and 
seminoma, but not in nonseminomatous male germ cell tumors. Mod 
Pathol. 2008;21(11):1337–44.
 24. Peltomaki P. DNA methylation changes in human testicular cancer. 
Biochim Biophys Acta. 1991;1096(3):187–96.
 25. Smiraglia DJ, Szymanska J, Kraggerud SM, Lothe RA, Peltomaki P, Plass C. 
Distinct epigenetic phenotypes in seminomatous and nonseminoma-
tous testicular germ cell tumors. Oncogene. 2002;21(24):3909–16.
 26. Wermann H, Stoop H, Gillis AJ, Honecker F, van Gurp RJ, Ammerpohl O, 
et al. Global DNA methylation in fetal human germ cells and germ cell 
tumours: association with differentiation and cisplatin resistance. J Pathol. 
2010;221(4):433–42.
 27. Gkountela S, Zhang KX, Shafiq TA, Liao WW, Hargan-Calvopina J, Chen PY, 
et al. DNA demethylation dynamics in the human prenatal germline. Cell. 
2015;161(6):1425–36.
 28. Guo F, Yan L, Guo H, Li L, Hu B, Zhao Y, et al. The transcriptome and 
DNA methylome landscapes of human primordial germ cells. Cell. 
2015;161(6):1437–52.
 29. Tang WW, Dietmann S, Irie N, Leitch HG, Floros VI, Bradshaw CR, et al. A 
unique gene regulatory network resets the human germline epigenome 
for development. Cell. 2015;161(6):1453–67.
 30. Benesova M, Trejbalova K, Kucerova D, Vernerova Z, Hron T, Szabo A, et al. 
Overexpression of TET dioxygenases in seminomas associates with low 
levels of DNA methylation and hydroxymethylation. Mol Carcinog. 2017. 
doi:10.1002/mc.22638.
 31. Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of tet 
proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell 
mass specification. Nature. 2010;466(7310):1129–33.
 32. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 
5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 
2011;333(6047):1303–7.
 33. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can 
convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. 
Science. 2011;333(6047):1300–3.
 34. Yamaguchi S, Shen L, Liu Y, Sendler D, Zhang Y. Role of Tet1 in erasure of 
genomic imprinting. Nature. 2013;504(7480):460–4.
 35. Kagiwada S, Kurimoto K, Hirota T, Yamaji M, Saitou M. Replication-coupled 
passive DNA demethylation for the erasure of genome imprints in mice. 
EMBO J. 2013;32(3):340–53.
 36. Rengstl B, Newrzela S, Heinrich T, Weiser C, Thalheimer FB, Schmid F, et al. 
Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin 
cells lead to giant multinucleated Reed-Sternberg cells. Proc Natl Acad 
Sci USA. 2013;110(51):20729–34.
 37. Strissel PL, Ellmann S, Loprich E, Thiel F, Fasching PA, Stiegler E, et al. 
Early aberrant insulin-like growth factor signaling in the progression 
to endometrial carcinoma is augmented by tamoxifen. Int J Cancer. 
2008;123(12):2871–9.
 38. Kassiotis G. Endogenous retroviruses and the development of cancer. J 
Immunol. 2014;192(4):1343–9.
Page 17 of 17Benešová et al. Retrovirology  (2017) 14:20 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 39. Muroi Y, Sakurai T, Hanashi A, Kubota K, Nagaoka K, Imakawa K. 
CD9 regulates transcription factor GCM1 and ERVWE1 expression 
through the cAMP/protein kinase A signaling pathway. Reproduction. 
2009;138(6):945–51.
 40. von Hochstetter AR, Sigg C, Saremaslani P, Hedinger C. The signifi-
cance of giant cells in human testicular seminomas. Virchows Arch A. 
1985;407(3):309–22.
 41. Butcher DN, Gregory WM, Gunter PA, Masters JR, Parkinson MC. The 
biological and clinical significance of HCG-containing cells in seminoma. 
Br J Cancer. 1985;51(4):473–8.
 42. Trejbalova K, Kovarova D, Blazkova J, Machala L, Jilich D, Weber J, et al. 
Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell 
line models and in long-term-infected individuals. Clin Epigenetics. 
2016;8:19. doi:10.1186/s13148-016-0185-6.
 43. Bestor TH, Tycko B. Creation of genomic methylation patterns. Nat Genet. 
1996;12(4):363–7.
 44. Roulois D, Yau HL, Singhania R, Wang YD, Danesh A, Shen SY, et al. DNA-
demethylating agents target colorectal cancer cells by inducing viral 
mimicry by endogenous transcripts. Cell. 2015;162(5):961–73.
 45. Chiappinelli KB, Strissel PL, Desrichard A, Li HL, Henke C, Akman B, et al. 
Inhibiting DNA methylation causes an interferon response in cancer via 
dsRNA including endogenous retroviruses. Cell. 2015;162(5):974–86.
 46. Stengel S, Fiebig U, Kurth R, Denner J. Regulation of human endogenous 
retrovirus-K expression in melanomas by CpG methylation. Gene Chro-
mosome Cancer. 2010;49(5):401–11.
 47. Santoni FA, Guerra J, Luban J. HERV-H RNA is abundant in human embry-
onic stem cells and a precise marker for pluripotency. Retrovirology. 
2012;9:111.
 48. Friedli M, Turelli P, Kapopoulou A, Rauwel B, Castro-Diaz N, Rowe HM, et al. 
Loss of transcriptional control over endogenous retroelements during 
reprogramming to pluripotency. Genome Res. 2014;24(8):1251–9.
 49. Fuchs NV, Loewer S, Daley GQ, Izsvak Z, Lower J, Lower R. Human endog-
enous retrovirus K (HML-2) RNA and protein expression is a marker for 
human embryonic and induced pluripotent stem cells. Retrovirology. 
2013;10:115.
